Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Clinical trial NCT03230318 · COMPLETED
Trial details
- NCT number
- NCT03230318
- Sponsor
- Basilea Pharmaceutica
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-28
- Primary completion
- 2022-10-25
- Enrollment
- 148
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.